TransMedics Group, Inc. (NASDAQ:TMDX) Shares Bought by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC grew its stake in TransMedics Group, Inc. (NASDAQ:TMDX) by 3.1% in the 1st quarter, according to its most recent filing with the SEC. The firm owned 730,010 shares of the company’s stock after buying an additional 21,737 shares during the quarter. Allspring Global Investments Holdings LLC owned 2.23% of TransMedics Group worth $53,977,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in the stock. Rhumbline Advisers lifted its stake in TransMedics Group by 2.5% in the third quarter. Rhumbline Advisers now owns 46,595 shares of the company’s stock worth $2,551,000 after acquiring an additional 1,123 shares during the last quarter. Envestnet Asset Management Inc. lifted its position in shares of TransMedics Group by 104.0% during the 3rd quarter. Envestnet Asset Management Inc. now owns 80,752 shares of the company’s stock worth $4,421,000 after purchasing an additional 41,168 shares during the last quarter. Qube Research & Technologies Ltd grew its stake in shares of TransMedics Group by 31.2% during the third quarter. Qube Research & Technologies Ltd now owns 84,450 shares of the company’s stock worth $4,624,000 after purchasing an additional 20,081 shares in the last quarter. Lazard Asset Management LLC increased its holdings in TransMedics Group by 13,809.8% in the third quarter. Lazard Asset Management LLC now owns 73,722 shares of the company’s stock valued at $4,036,000 after buying an additional 73,192 shares during the last quarter. Finally, Alberta Investment Management Corp raised its stake in TransMedics Group by 311.4% in the third quarter. Alberta Investment Management Corp now owns 19,889 shares of the company’s stock valued at $1,089,000 after buying an additional 15,055 shares in the last quarter. 99.67% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at TransMedics Group

In other news, insider Tamer I. Khayal sold 4,947 shares of the company’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $80.36, for a total transaction of $397,540.92. Following the completion of the sale, the insider now owns 25,185 shares in the company, valued at $2,023,866.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director David Weill sold 1,193 shares of the firm’s stock in a transaction dated Wednesday, May 29th. The shares were sold at an average price of $141.65, for a total value of $168,988.45. Following the completion of the sale, the director now owns 10,732 shares in the company, valued at $1,520,187.80. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Tamer I. Khayal sold 4,947 shares of the stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $80.36, for a total value of $397,540.92. Following the transaction, the insider now directly owns 25,185 shares of the company’s stock, valued at $2,023,866.60. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 275,501 shares of company stock worth $32,158,039. 7.00% of the stock is currently owned by insiders.

Analysts Set New Price Targets

TMDX has been the subject of several analyst reports. Cantor Fitzgerald assumed coverage on TransMedics Group in a research report on Thursday, June 6th. They set an “overweight” rating and a $161.00 price objective for the company. JPMorgan Chase & Co. upped their price target on TransMedics Group from $105.00 to $127.00 and gave the company an “overweight” rating in a report on Wednesday, May 1st. TD Cowen raised their price objective on shares of TransMedics Group from $130.00 to $175.00 and gave the stock a “buy” rating in a report on Friday, June 7th. Canaccord Genuity Group boosted their price objective on shares of TransMedics Group from $102.00 to $117.00 and gave the stock a “buy” rating in a research report on Wednesday, May 1st. Finally, Stephens started coverage on shares of TransMedics Group in a research report on Tuesday, June 4th. They issued an “overweight” rating and a $151.00 target price on the stock. One analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $133.88.

TransMedics Group Stock Performance

Shares of NASDAQ:TMDX opened at $148.97 on Wednesday. TransMedics Group, Inc. has a 1-year low of $36.42 and a 1-year high of $154.14. The company has a current ratio of 9.72, a quick ratio of 8.76 and a debt-to-equity ratio of 3.18. The firm has a fifty day moving average price of $133.45 and a 200 day moving average price of $100.59.

TransMedics Group (NASDAQ:TMDX) last announced its earnings results on Tuesday, April 30th. The company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.40. The business had revenue of $96.90 million during the quarter, compared to the consensus estimate of $83.78 million. TransMedics Group had a negative net margin of 3.43% and a positive return on equity of 7.95%. The business’s quarterly revenue was up 132.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.08) earnings per share. On average, equities analysts anticipate that TransMedics Group, Inc. will post 0.77 EPS for the current fiscal year.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.